Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells

Cancer Science

Volumn 102, Issue 12, 2011, Pages 2157-2163

  Yamada, Tadaaki ^a   Bando, Hideaki ^a   Takeuchi, Shinji ^a   Kita, Kenji ^a   Li, Qi ^a   Wang, Wei ^a   Akinaga, Shiro ^b   Nishioka, Yasuhiko ^c   Sone, Saburo ^c   Yano, Seiji ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; BIW 8962; CHIMERIC ANTIBODY; GANGLIOSIDE GM2; KM 8927; KM 966; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; GENETIC ENGINEERING; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPLEMENT SYSTEM PROTEINS; G(M2) GANGLIOSIDE; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM METASTASIS; SMALL CELL LUNG CARCINOMA;

EID: 81855166207     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02093.x     Document Type: Article

References (29)

1. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355: 479-85.
2. Quint LE, Francis IR, Wahl RL, Gross BH. Imaging of Lung Cancer: Lung Cancer, Principles and Practice. Philadelphia: Lippincott-Raven, 1996; 437-70.
3. Kenzaki K, Sakiyama S, Tomimoto H et al. Clinical analysis of elderly patients with primary lung cancer. Kyobu Geka 2010;63: 519-23; discussion 524-6.
4. Goya T, Asamura H, Yoshimura H et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 2005; 50: 227-34.
5. Mountain CF. A new international staging system for lung cancer. Chest 1986; 4(Suppl): 225S-33S.
6. Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods Mol Biol 2009; 471: 469-86.
7. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997; 111: 1718-23.
8. Sullivan FJ. Palliative Radiotherapy for Lung Cancer: Lung Cancer, Principles and Practice. Philadelphia: Lippincott-Raven, 1996; 775-89.
9. Portoukalian J, Zwingelstein G, Dore JF, Bourgoin JJ. Studies of a ganglioside fraction extracted from human malignant melanoma. Biochimie 1976; 58: 1285-7.
10. Akasako Y, Nara K, Nagai Y, Hashimoto Y. Inhibition of ganglioside synthesis reduces the neuronal survival activity of astrocytes. Neurosci Lett 2011; 488: 199-203.
11. Ravindranath MH, Tsuchida T, Morton DL, Irie RF. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 1991; 67: 3029-35.
12. Laferte S, Fukuda MN, Fukuda M, Dell A, Dennis JW. Glycosphingolipids of lectin-resistant mutants of the highly metastatic mouse tumor cell line, MDAY-D2. Cancer Res 1987; 47: 150-9.
13. Hanibuchi M, Yano S, Nishioka Y, Yanagawa H, Kawano T, Sone S. Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice. Int J Cancer 1998; 78: 480-5.
14. Hanibuchi M, Yano S, Nishioka Y, Yanagawa H, Sone S. Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes. Jpn J Cancer Res 1996; 87: 497-504.
15. Fukumoto H, Nishio K, Ohta S, Hanai N, Saijo N. Reversal of adriamycin resistance with chimeric anti-ganglioside GM2 antibody. Int J Cancer 1996; 67: 676-80.
16. Hanibuchi M, Yano S, Nishioka Y, Yanagawa H, Miki T, Sone S. Immunological circumvention of multiple organ metastases of multidrug resistant human small cell lung cancer cells by mouse-human chimeric anti-ganglioside GM2 antibody KM966. Clin Exp Metastasis 2000; 18: 353-60.
17. Langerak A, River G, Mitchell E, Cheema P, Shing M. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports. Clin Colorectal Cancer 2009; 8: 49-54.
18. Heun J, Holen K. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer 2007; 6: 529-31.
19. Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park) 2006; 20:1373-82; discussion 1382, 1392-4, 1397.
20. Helbling D, Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol 2007; 18: 963-4.
21. Ura T. The current status of development of anti-EGFR antibodies. Gan To Kagaku Ryoho 2010; 37: 777-81.
22. Shitara K. Potelligent antibodies as next generation therapeutic antibodies. Yakugaku Zasshi 2009; 129: 3-9.
23. Tanaka T, Kitamura F, Nagasaka Y, Kuida K, Suwa H, Miyasaka M. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor β chain monoclonal antibody in mice. J Exp Med 1993; 178: 1103-7.
24. Nishioka Y, Yano S, Fujiki F et al. Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction: the possibility of immunological overcoming of multidrug resistance. Int J Cancer 1997; 71: 170-7.
25. Green LM, Reade JL, Ware CF. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods 1984; 70: 257-68.
26. Yano S, Nishioka Y, Izumi K et al. Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. Int J Cancer 1996; 67: 211-7.
27. Helbling D, Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol 2007; 18: 963-4.
28. Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci 2009; 100: 1566-72.
29. Klehr M, Koehl U, Mühlenhoff M et al. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC). J Immunother 2009; 32: 442-51.